Roanna Ruiz
Stock Analyst at Leerink Partners
(0.81)
# 3,735
Out of 4,874 analysts
63
Total ratings
33.33%
Success rate
-16.59%
Average return
Main Sectors:
Stocks Rated by Roanna Ruiz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKBA Akebia Therapeutics | Initiates: Outperform | $7 | $3.74 | +87.17% | 1 | Apr 28, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $5 → $6 | $4.74 | +26.58% | 5 | Mar 7, 2025 | |
| CRMD CorMedix | Initiates: Outperform | $18 | $14.96 | +20.32% | 1 | Mar 7, 2025 | |
| LXRX Lexicon Pharmaceuticals | Downgrades: Market Perform | $1 | $0.93 | +7.61% | 1 | Mar 4, 2025 | |
| VIR Vir Biotechnology | Maintains: Outperform | $18 → $20 | $5.31 | +276.65% | 4 | Jan 13, 2025 | |
| SPRY ARS Pharmaceuticals | Maintains: Outperform | $26 → $27 | $18.08 | +49.34% | 4 | Jan 13, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Outperform | $12 → $13 | $3.25 | +300.00% | 3 | Oct 25, 2024 | |
| ARDX Ardelyx | Initiates: Outperform | $14 | $3.69 | +279.92% | 1 | Apr 5, 2024 | |
| UTHR United Therapeutics | Initiates: Outperform | $330 | $284.09 | +16.16% | 1 | Feb 5, 2024 | |
| CYTK Cytokinetics | Initiates: Outperform | $58 | $33.91 | +71.04% | 1 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $25 | $74.33 | -66.37% | 1 | Apr 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | $49 | $7.51 | +552.46% | 10 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $13 | $3.98 | +226.63% | 7 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $8 → $6 | $3.53 | +69.97% | 6 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $18.45 | +2.98% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $110 → $120 | $80.74 | +48.63% | 3 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $75 → $50 | $7.14 | +600.28% | 7 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $40 | $15.90 | +151.57% | 6 | Oct 19, 2022 |
Akebia Therapeutics
Apr 28, 2025
Initiates: Outperform
Price Target: $7
Current: $3.74
Upside: +87.17%
Xeris Biopharma Holdings
Mar 7, 2025
Maintains: Outperform
Price Target: $5 → $6
Current: $4.74
Upside: +26.58%
CorMedix
Mar 7, 2025
Initiates: Outperform
Price Target: $18
Current: $14.96
Upside: +20.32%
Lexicon Pharmaceuticals
Mar 4, 2025
Downgrades: Market Perform
Price Target: $1
Current: $0.93
Upside: +7.61%
Vir Biotechnology
Jan 13, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $5.31
Upside: +276.65%
ARS Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $26 → $27
Current: $18.08
Upside: +49.34%
Aquestive Therapeutics
Oct 25, 2024
Maintains: Outperform
Price Target: $12 → $13
Current: $3.25
Upside: +300.00%
Ardelyx
Apr 5, 2024
Initiates: Outperform
Price Target: $14
Current: $3.69
Upside: +279.92%
United Therapeutics
Feb 5, 2024
Initiates: Outperform
Price Target: $330
Current: $284.09
Upside: +16.16%
Cytokinetics
Aug 15, 2023
Initiates: Outperform
Price Target: $58
Current: $33.91
Upside: +71.04%
Apr 11, 2023
Initiates: Market Perform
Price Target: $25
Current: $74.33
Upside: -66.37%
Feb 9, 2023
Reiterates: Market Perform
Price Target: $49
Current: $7.51
Upside: +552.46%
Jan 27, 2023
Maintains: Outperform
Price Target: $12 → $13
Current: $3.98
Upside: +226.63%
Jan 27, 2023
Maintains: Market Perform
Price Target: $8 → $6
Current: $3.53
Upside: +69.97%
Dec 20, 2022
Initiates: Outperform
Price Target: $19
Current: $18.45
Upside: +2.98%
Nov 15, 2022
Maintains: Outperform
Price Target: $110 → $120
Current: $80.74
Upside: +48.63%
Nov 3, 2022
Maintains: Market Perform
Price Target: $75 → $50
Current: $7.14
Upside: +600.28%
Oct 19, 2022
Maintains: Market Perform
Price Target: $60 → $40
Current: $15.90
Upside: +151.57%